

Special Issue

Prospects in Transgenic Technology 2020

Message from the Guest Editors

Dear colleagues, With the advent of gene editing technologies, the ability to manipulate genomes has become amenable to nearly all species. Gene modification protocols that lead to new ways of generating genetically engineered model systems are being developed at an exponential pace, with new techniques reported almost daily. With this technology, we may be able to easily generate models of diseases affecting both humans and other animals, increase food production worldwide, and perform gene therapy to alleviate disease, among the many possibilities. However, success should be based on an understanding of when to use newer vs. established technologies. Scientists should be aware of both expected and unexpected consequences of the particular method chosen for gene modification. Analyses and assessments that take into account such consequences are critical for acceptance by society, as is an ethical approach to determining what uses such technology can have. This Special Issue of *Genes* welcomes original research manuscripts and review papers that address the science and ethics of gene modification.

Guest Editors

Dr. Wojtek Auerbach

1. Embryonic Stem Cells Technologies, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA

2. President International Society for Transgenic Technologies

Dr. Jan Parker-Thornburg

Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Deadline for manuscript submissions

closed (29 February 2020)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/27883

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))